Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750336 | 0.89 | RPS6KB1 (0.42) | L3MBTL1KDM4EMEN1KMT2ACYP3A4 | |
| SCHEMBL5141799 | 0.87 | MEN1 (0.52) | L3MBTL1GAAKDM4EMEN1KMT2A | |
| SCHEMBL5521702 | 0.83 | KCNH2 (0.53) | L3MBTL1HSD17B10GAAKDM4CHCAR3 | |
| SCHEMBL1260412 | 0.83 | L3MBTL1 (0.54) | L3MBTL1HSD17B10GAAKDM4EHCAR3 | |
| SCHEMBL3747860 | 0.78 | L3MBTL1 (0.56) | L3MBTL1HSD17B10GAAKDM4EHCAR3 | |
| SCHEMBL14382628 | 0.78 | L3MBTL1 (0.63) | L3MBTL1HSD17B10GAACYP3A4CYP2C19 | |
| SCHEMBL5108137 | 0.77 | L3MBTL1 (0.65) | L3MBTL1HSD17B10GAACYP3A4CYP2C19 | |
| SCHEMBL4726848 | 0.73 | KDM4E (0.58) | L3MBTL1HSD17B10GAAKDM4EHCAR3 | |
| SCHEMBL12051162 | 0.73 | KCNH2 (0.53) | L3MBTL1GAACYP3A4CYP2C19KCNH2 | |
| SCHEMBL1260727 | 0.72 | CYP3A4 (0.61) | KDM4EKDM6BKDM4AKDM5CKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838537-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838537-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838537-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| EP-1587585-B1 | ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF RNA-DEPENDENT RNA (VIRAL) POLYMERASES | BOEHRINGER INGELHEIM INT (DE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1587585-B1 | ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF RNA-DEPENDENT RNA (VIRAL) POLYMERASES | BOEHRINGER INGELHEIM INT (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20080119490-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119490-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119490-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7323470-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-29 | — | — | US | disclosed |
| US-7323470-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-29 | — | — | US | disclosed |
| US-7323470-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-29 | — | — | US | disclosed |
| US-7098231-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-29 | — | — | US | disclosed |
| US-20060189672-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
| EP-1587585-A1 | ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF RNA-DEPENDENT RNA (VIRAL) POLYMERASES | Boehringer Ingelheim International GmbH (DE) | 2005-10-26 | — | — | EP | disclosed |
| US-20040186125-A1 | E.g , 3-cyclohexyl-2-furan-3-yl-1Hindole-5-carboxylic acid; hepatitis C viricides that target RNA dependent RNA polymerases (Ns5B) in mammals, an enzyme essential to viral replication; used in conjunction with an mmunomodulatory agent, such as beta -, delta - gamma -, and omega -interferon | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-23 | — | — | US | disclosed |
| WO-2004064925-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189672-A1 | Viral polymerase inhibitors | POLM, POLR2A, POLR2H | L3MBTL1 117/4885HSD17B10 3213/4885GAA 776/4885 |
| US-20080119490-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | L3MBTL1 584/4885HSD17B10 3254/4885GAA 994/4885 |
| US-20040186125-A1 | E.g , 3-cyclohexyl-2-furan-3-yl-1Hindole-5-carboxylic acid; hepatitis C viricides that target RNA dependent RNA polymerases (Ns5B) in mammals, an enzyme essential to viral replication; used in conjunction with an mmunomodulatory agent, such as beta -, delta - gamma -, and omega -interferon | IFNAR1, IFNG, EIF2AK2 | L3MBTL1 2103/4885HSD17B10 2430/4885GAA 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.